Stock 300653 YANTAI ZHENGHAI BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Yantai Zhenghai Biotechnology Co., Ltd.

Equities

300653

CNE100002NZ1

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
23.19 CNY +0.91% Intraday chart for Yantai Zhenghai Biotechnology Co., Ltd. -0.51% -20.09%
Apr. 28 Yantai Zhenghai Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 03 Tranche Update on Yantai Zhenghai Biotechnology Co., Ltd.'s Equity Buyback Plan announced on December 20, 2023. CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
YANTAI ZHENGHAI BIOTECHNOLOGY CO., LTD. Stock Yantai Zhenghai Biotechnology Co., Ltd.
-20.09% 577M -
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-4.91% 11.09B
A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
-1.95% 8.56B
C
GLAUKOS CORPORATION Stock Glaukos Corporation
+41.43% 5.62B
B+
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
-24.88% 4.41B
C
AXONICS, INC. Stock Axonics, Inc.
+7.52% 3.41B
C-
ENOVIS CORPORATION Stock Enovis Corporation
-15.63% 2.6B
B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-12.74% 2.07B - -
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-13.26% 1.92B -
DOUBLE MEDICAL TECHNOLOGY INC. Stock Double Medical Technology Inc.
-29.81% 1.63B
C-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300653 Stock
  4. Ratings Yantai Zhenghai Biotechnology Co., Ltd.